PROPANC BIOPHARMA, INC. Debt Instrument, Convertible, Conversion Price, Increase
PROPANC BIOPHARMA, INC. (PPCB) reported Debt Instrument, Convertible, Conversion Price, Increase of $0.011 for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:DebtInstrumentConvertibleConversionPriceIncrease · last filed 2019-05-15
- PROPANC BIOPHARMA, INC. debt instrument, convertible, conversion price, increase for the quarter ending 2019-03-31 was $0.01.
- PROPANC BIOPHARMA, INC. debt instrument, convertible, conversion price, increase for the quarter ending 2018-12-31 was $0.04.
- PROPANC BIOPHARMA, INC. debt instrument, convertible, conversion price, increase for the quarter ending 2018-09-30 was $0.04.
USD
| Period end | Debt Instrument, Convertible, Conversion Price, Increase 3 month | Debt Instrument, Convertible, Conversion Price, Increase 6 month | Debt Instrument, Convertible, Conversion Price, Increase 9 month |
|---|---|---|---|
| 2019-03-31 | $0.01 10-Q · filed 2019-05-15 | $0.04 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $0.04 10-Q · filed 2019-05-15 | $0.04 10-Q · filed 2019-02-14 | |
| 2018-09-30 | $0.04 10-Q · filed 2019-05-15 |
USD/shares
| Period end | Debt Instrument, Convertible, Conversion Price, Increase 3 month | Debt Instrument, Convertible, Conversion Price, Increase 6 month | Debt Instrument, Convertible, Conversion Price, Increase 9 month |
|---|---|---|---|
| 2019-03-31 | $0.01 10-Q · filed 2019-05-15 | $0.04 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $0.04 10-Q · filed 2019-05-15 | $0.04 10-Q · filed 2019-02-14 | |
| 2018-09-30 | $0.04 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |